Verrica Pharmaceuticals Q3 Adj. EPS $(0.32) Beats $(0.36) Estimate, Sales $2.92M Beat $510.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Verrica Pharmaceuticals reported Q3 adjusted losses of $(0.32) per share, beating the analyst consensus estimate of $(0.36) by 11.11%. The company also reported quarterly sales of $2.92 million, surpassing the analyst consensus estimate of $510.00 thousand by 471.96%. However, this represents a 557.14% decrease in earnings and a 64.94% decrease in sales compared to the same period last year.
November 09, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Verrica Pharmaceuticals reported better than expected Q3 results but showed a significant decrease in earnings and sales compared to the same period last year.
While Verrica Pharmaceuticals beat Q3 estimates, the significant year-over-year decreases in earnings and sales could potentially offset any positive impact from the earnings beat. Investors may view the company's performance as mixed, leading to a neutral short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100